Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by €2.4B – MedCity News
Galapagos said the planned business separation will leave the legacy company free to focus on developing cell therapies for cancer. An accompanying corporate restructuring will shave Galapagos’s headcount by 40%.